Yoo Okhee, Tang Edith, Hossain Md Lokman, von Ungern-Sternberg Britta S, Sommerfield David, Heath Chloe, Hauser Neil, Khan R Nazim, Locher Cornelia, Nguyen Minh, Lim Lee Yong
Discipline of Pharmacy, School of Allied Health, The University of Western Australia, Perth, WA 6009, Australia.
Institute for Pediatric Perioperative Excellence, The University of Western Australia, Perth, WA 6009, Australia.
Pharmaceutics. 2024 Aug 21;16(8):1099. doi: 10.3390/pharmaceutics16081099.
Oral liquid prednisolone medications have poor acceptance among paediatric patients due to ineffective masking of the bitterness taste of prednisolone. This study aimed to develop a child-friendly prednisolone tablet using a patented chewable chocolate-based delivery system (CDS) previously applied successfully to mask the bitterness tastes of midazolam and tramadol. Prednisolone sodium phosphate (PSP) and prednisolone base (PB) CDS tablets were prepared, and the manufacturing process was optimised using a design of experiments (DoE) approach. Stability was assessed by quantifying residual drug content via a validated HPLC assay. A pilot randomised crossover taste study involving 25 young adult volunteers evaluated taste-masking effectiveness against Redipred™, a commercial oral PSP liquid medicine. The results showed that the PSP CDS tablet was chemically stable following storage for three months at ambient temperature, while the PB CDS tablet was unstable. The optimised PSP CDS tablet, manufactured at 50 °C with a stirring time of 26 h, was found to release over 80% of its drug load within 20 min in 0.1 M HCl and had a significantly better mean taste score compared to Redipred™ (7.08 ± 2.40 vs. 5.60 ± 2.33, = 0.03). Fifty six percent of the participants preferred the PSP CDS tablet. In conclusion, compared to Redipred™, the CDS technology provided a more effective taste masking of PSP, potentially offering a child-friendly prednisolone formulation with improved compliance, dosing accuracy, and storage stability.
由于无法有效掩盖泼尼松龙的苦味,口服泼尼松龙药物在儿科患者中的接受度较低。本研究旨在利用一种专利的基于巧克力的可咀嚼给药系统(CDS)开发一种适合儿童的泼尼松龙片剂,该系统此前已成功应用于掩盖咪达唑仑和曲马多的苦味。制备了磷酸泼尼松龙钠(PSP)和泼尼松龙碱(PB)CDS片剂,并采用实验设计(DoE)方法优化了生产工艺。通过经过验证的高效液相色谱法测定残留药物含量来评估稳定性。一项涉及25名年轻成年志愿者的随机交叉味觉试验研究评估了与市售口服PSP液体制剂Redipred™相比的味觉掩盖效果。结果表明,PSP CDS片剂在室温下储存三个月后化学性质稳定,而PB CDS片剂不稳定。发现在50°C下搅拌26小时制备的优化PSP CDS片剂在0.1 M HCl中20分钟内释放超过80%的药物负载,并且与Redipred™相比平均味觉评分显著更高(7.08±2.40对5.60±2.33,P = 0.03)。56%的参与者更喜欢PSP CDS片剂。总之,与Redipred™相比,CDS技术对PSP提供了更有效的味觉掩盖,有可能提供一种具有更好顺应性、给药准确性和储存稳定性的适合儿童的泼尼松龙制剂。